The Effect of Genetic Polymorphism upon Antineoplastic Sensitivity

References

1. ↵
   1. Hu S,
   2. Zang AH

   . Pharmacogenetics and cancer therapy. J Chin Oncol. 2005;14:108—110 (Chinese).

   OpenUrl
2. ↵
   1. Iyer L,
   2. Hall D,
   3. Das S, et al

   . Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther. 1999;65:576–582.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Ogura K,
   2. Ishikawa Y,
   3. Kaku T, et al

   . Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP -glucuronosyltransferase 1A4. Biochem Pharmacol. 2006;71:1358–1369.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   1. Lennard L,
   2. Gibson BE,
   3. Nicole T, et al

   . Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child. 1993;69:577–579.

   OpenUrlAbstract/FREE Full Text
5. ↵
   1. Zhang LR,
   2. Song DK,
   3. Zhang W, et al

   . Efficient screening method of the thiopurine methyltransferase polymorphisms for patients considering taking thiopurine drugs in a Chinese Han population in Henan Province (central China) Clínica Chimica Acta (2006) [Serial online] http://dx.doi.org/10.1016/j.cca.2006.07.010.
6. ↵
   1. Wang LW,
   2. Nquyen TV,
   3. Mclaughlin RW, et al

   . Human thiopurine S-methyltransferase pharmacogenetics: Variant allozyme misfolding and aggresome formation. PNAS. 2005;102:9394–9399.

   OpenUrlAbstract/FREE Full Text
7. ↵
   1. Xu CM

   . The progression of genetic polymorphism of chemotherapeutics metabolism enzyme. Foreign Medical Science (Genetics Section). 2003;26:156—159 (Chinese).

   OpenUrl
8. ↵
   1. Milano G,
   2. Etienne MC,
   3. Pierrefite V, et al

   . Dihydropyrimidine dehydrogenase deficiency and fluorouracil -related toxicity. Br J Cancer. 1999;79:627–630.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Salonga D,
   2. Danenberg KD,
   3. Johnson M, et al

   . Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000;6:1322–1327.

   OpenUrlAbstract/FREE Full Text
10. ↵
    1. Collie-Duguid ES,
    2. Etienne MC,
    3. Milano G, et al

    . Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics. 2000;10:217–223.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Sohn KJ,
    2. Croxford R,
    3. Yates Z, et al

    . Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. Natl Cancer Inst. 2004;96:134–144.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. Nakajima M,
    2. Kuroiwa Y,
    3. Yokoi T, et al

    . Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. Drug Metab Rev. 2002;34:865–877.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    1. Huang Z,
    2. Roy P,
    3. Waxman DJ, et al

    . Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N -dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol. 2000;59:961–972.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    1. Dai D,
    2. Zeldin DC,
    3. Blaisdell JA, et al

    . Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001;11:597–607.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. Dehal SS,
    2. Kupfer D

    . CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res. 1997;57: 3402–3406.

    OpenUrlAbstract/FREE Full Text
16. ↵
    1. Schuetz EG

    . Lessons from the CYP3A4 promoter. Mol Pharmacol. 2004;65:279–281.

    OpenUrlFREE Full Text
17. ↵
    1. Mandola MV,
    2. Stoehlmacher J,
    3. Muller-Weeks S, et al

    . A novel single nucleotide polymorphism within the 52 tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 2003;63:2898–2904.

    OpenUrlAbstract/FREE Full Text
18. ↵
    1. Lecomte T,
    2. Ferraz JM,
    3. Zinzindohoué F, et al

    . Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res. 2004;10:5880–5888.

    OpenUrlAbstract/FREE Full Text
19. ↵
    1. Marsh S,
    2. McKay JA,
    3. Cassidy J, et al

    . Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol. 2001;19:383–386.

    OpenUrlPubMedWeb of Science
20. ↵
    1. lacopetta B,
    2. Grieu F,
    3. Joseph D, et al

    . A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer. 2001;85:827–830.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    1. Park DJ,
    2. Stoehlmacher J,
    3. Zhang W, et al

    . Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis. 2002;17:46–49.

    OpenUrlCrossRefPubMedWeb of Science
22. ↵
    1. Watanabe T,
    2. Wu TT,
    3. Catalano PJ, et al

    . Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Eng J Med. 2001;344:1196–1206.

    OpenUrlCrossRefPubMedWeb of Science
23. ↵
    1. Ulrich CM,
    2. Biqler J,
    3. Velicer CM, et al

    . Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomark Prev. 2000;9:1381–1385.

    OpenUrlAbstract/FREE Full Text
24. ↵
    1. Zhou CC

    . Application of pharmaceutical genetics in chemotherapy of tumor. Tumor. 2006;26:109—111 (Chinese).

    OpenUrl
25. ↵
    1. Qiao Y,
    2. Spitz MR,
    3. Shen H, et al

    . Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD /ERCC2 genotypes. Carcinogenesis. 2002;23:295–299.

    OpenUrlCrossRefPubMedWeb of Science